MedTrace Logo

Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

NCT02932488 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-06-27

No results posted yet for this study

Summary

The purpose of this study is to show that PET-MR imaging can be used for obtaining a pharmacodynamic profile of drugs. By using the 5-HT1B receptor as target we also aim to find effect areas and sizes of the 5-HT1B receptor agonist sumatriptan.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Sumatriptan

Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks

Sponsors & Collaborators

  • Gitte Moos Knudsen

    lead OTHER

Principal Investigators

  • Gitte M Knudsen, MD, DMSc · Neurobiology Research Unit, Rigshospitalet

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-06-30
Completion
2019-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02932488 on ClinicalTrials.gov